Here's Why NRx Pharmaceuticals Stock Dropped Monday

·2-min read
Here's Why NRx Pharmaceuticals Stock Dropped Monday

Shares of COVID-19 stock NRx Pharmaceuticals (NASDAQ: NRXP) fell 24% Monday after soaring last week. Last week, NRX Pharmaceuticals stock nearly tripled in response to a positive clinical trial readout for its lead candidate, Zyesami, and a potential solution to a serious logistics problem. On July 19, NRx Pharmaceuticals rose after reporting positive biomarker data from a late-stage clinical trial with Zyesami.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting